Lista de obras -

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

artículo científico publicado en 2008

A journey through infectious risk associated with ruxolitinib

scientific article published on 29 August 2019

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

artículo científico publicado en 2014

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis

artículo científico publicado en 2020

Advances in understanding the pathogenesis of familial myeloproliferative neoplasms

artículo científico publicado en 2017

Blast phase of essential thrombocythemia: A single center study

artículo científico publicado en 2009

Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations

artículo científico publicado en 2007

Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment

scientific article published on 19 August 2005

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

artículo científico publicado en 2016

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

artículo científico publicado en 2015

Facing erythrocytosis: Results of an international physician survey

artículo científico publicado en 2019

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

artículo científico publicado en 2007

HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia

artículo científico publicado en 2007

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

scientific article published on 07 January 2021

High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma

artículo científico publicado en 2009

How I treat essential thrombocythemia

artículo científico publicado en 2016

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

artículo científico publicado en 2019

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas

article

Impaired Virus-Specific T Cell Responses in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

scientific article published on 25 June 2020

Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.

artículo científico publicado en 2010

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

artículo científico publicado en 2010

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

artículo científico publicado en 2007

JAK inhibitors and risk of B-cell lymphomas

artículo científico publicado en 2019

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders

artículo científico publicado en 2006

LNK mutations in familial myeloproliferative neoplasms.

artículo científico publicado en 2016

Leukemic transformation of polycythemia vera: a single center study of 23 patients

artículo científico publicado en 2005

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

scientific article published on 01 November 2004

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

artículo científico publicado en 2004

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

artículo científico publicado en 2012

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

scientific article published on 07 May 2019

Myeloproliferative and lymphoproliferative disorders: State of the art

artículo científico publicado en 2019

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

scientific article published on 13 October 2020

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

artículo científico publicado en 2008

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

artículo científico publicado en 2005

Role of the molecular staging and response in the management of follicular lymphoma patients

scientific article published on 01 June 2006

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

artículo científico publicado en 2017

Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms

artículo científico publicado en 2019

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

scientific article published on 29 May 2019

Second cancers in MPN: Survival analysis from an international study

artículo científico publicado en 2019

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

scientific article published on 10 May 2019

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

artículo científico publicado en 2019

Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires

artículo científico publicado en 2009

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance

artículo científico publicado en 2020

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

scientific article published on 12 December 2019

Validation of cytogenetic-based risk stratification in primary myelofibrosis.

artículo científico publicado en 2010

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

artículo científico publicado en 2020

Lista de obras de

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

A journey through infectious risk associated with ruxolitinib

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis

Advances in understanding the pathogenesis of familial myeloproliferative neoplasms

Blast phase of essential thrombocythemia: A single center study

Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations

Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Facing erythrocytosis: Results of an international physician survey

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma

How I treat essential thrombocythemia

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas

Impaired Virus-Specific T Cell Responses in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

JAK inhibitors and risk of B-cell lymphomas

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders

LNK mutations in familial myeloproliferative neoplasms.

Leukemic transformation of polycythemia vera: a single center study of 23 patients

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Myeloproliferative and lymphoproliferative disorders: State of the art

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Role of the molecular staging and response in the management of follicular lymphoma patients

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Second cancers in MPN: Survival analysis from an international study

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

Validation of cytogenetic-based risk stratification in primary myelofibrosis.

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis